Medicare Cuts Cost of 10 Common Drugs Covered by Part D

被引：0
|
作者：
Anderer, Samantha
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2024年 / 332卷 / 14期
关键词：
D O I：
10.1001/jama.2024.18192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program
    Ma, Iris
    Tisdale, Rebecca L.
    Vail, Daniel
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2021, 14 (12): : 1215 - 1223
  • [32] Role of Specialty Drugs in Rising Drug Prices for Medicare Part D
    Hayford, Tamara B.
    JAMA HEALTH FORUM, 2024, 5 (05): : E241188
  • [33] Medicare Part D payments for brand and generic drugs prescribed by dermatologists
    Powell, Helen B.
    Adamson, Adewole S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : 575 - 577
  • [34] Access, Benefit Design, and Antipsychotic Drugs in the Medicare Part D Program
    Fung, Vicki
    Price, Mary
    Hsu, John
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 188 - 188
  • [35] Impact of Medicare Part D Plan Features on Use of Generic Drugs
    Tang, Yan
    Gellad, Walid F.
    Men, Aiju
    Donohue, Julie M.
    MEDICAL CARE, 2014, 52 (06) : 541 - 548
  • [36] Coverage and prior authorization of psychotropic drugs under Medicare Part D
    Huskamp, Haiden A.
    Stevenson, David G.
    Donohue, Julie M.
    Newhouse, Joseph P.
    Keating, Nancy L.
    PSYCHIATRIC SERVICES, 2007, 58 (03) : 308 - 310
  • [37] Prescribing of low- versus high-cost Part B drugs in Medicare Advantage and traditional Medicare
    Anderson, Kelly E.
    Polsky, Daniel
    Dy, Sydney
    Sen, Aditi P.
    HEALTH SERVICES RESEARCH, 2022, 57 (03) : 537 - 547
  • [38] ANALYSIS OF FORMULARY COVERAGE AND COST OF HUMAN IMMUNODEFICIENCY VIRUS ANTIRETROVIRAL DRUGS IN MEDICARE PART D (2006-2015)
    Alshahrani, A.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    Araujo, L.
    Eguale, T.
    VALUE IN HEALTH, 2017, 20 (05) : A366 - A366
  • [39] Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017
    Seiger, Kira
    Mostaghimi, Arash
    Silk, Ann W.
    Schmults, Chrysalyne D.
    Ruiz, Emily Stamell
    JAMA ONCOLOGY, 2020, 6 (01) : 154 - 156
  • [40] ANALYSIS OF FORMULARY COVERAGE AND COST OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN MEDICARE PART D
    Alghamdi, A.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    VALUE IN HEALTH, 2017, 20 (05) : A152 - A152
12345